Moxham has over 20 years of drug discovery experience, primarily at Eli Lilly and Company where he most recently served as vice president, quantitative biology. In this role, he helped grow Lilly’s oncology pipeline, developed critical biopharma and academic partnerships and established a state-of-the-art lab facility focused on preclinical and translational research. Previously, he was associate vice president, oncology research at Lilly where he established and led the company’s biomarker group. Moxham began his tenure at Lilly as a research scientist and received several awards from the company, including the Lilly Research Laboratories President’s Award and the Eli Lilly and Co. Global Quality Advocate Award. He also spent two years as a senior research fellow at Merck, where he supported a portfolio of projects centered on Alzheimer’s disease and led work that resulted in a clinical candidate. Moxham serves on the external review boards of the Long Island Bioscience Hub and the Alzheimer’s Drug Discovery Foundation, and on the advisory board of Science Exchange. He has a B.S. in biological sciences from Cornell University and a Ph.D. in molecular and cellular pharmacology from the State University of New York at Stony Brook. He also conducted postdoctoral training at SUNY Stony Brook, sponsored by the National Institutes of Health.